Acurx Pharmaceuticals Secures New Financing to Advance Pipeline

Acurx Pharmaceuticals ( (ACXP) ) has shared an announcement.

On April 15–16, 2026, Acurx Pharmaceuticals, Inc. entered into agreements for a registered direct offering and concurrent private placement of its securities, raising approximately $2.5 million in upfront gross proceeds and issuing common stock or pre-funded warrants priced at $3.03 per share. In the private placement, investors also received short-term Series H warrants to purchase up to 1,650,170 shares at $2.78 per share, potentially providing an additional $4.6 million in gross proceeds if fully exercised.

The financing, expected to close around April 16, 2026, will be used for working capital and general corporate purposes as the company advances its late-stage antibiotic pipeline, including Phase 3–ready ibezapolstat for C. difficile infection. Acurx accepted customary lock-up and anti–variable-rate covenants, engaged H.C. Wainwright & Co. as exclusive placement agent on a 6% fee, and acknowledged that the unlisted warrants may be illiquid, underscoring both the company’s funding needs and the structured nature of its capital-raising strategy.

The most recent analyst rating on (ACXP) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Acurx Pharmaceuticals stock, see the ACXP Stock Forecast page.

Spark’s Take on ACXP Stock

According to Spark, TipRanks’ AI Analyst, ACXP is a Neutral.

Score is primarily constrained by weak financial performance (no revenue, worsening losses and cash burn) and a bearish technical backdrop with the stock below key moving averages. Corporate events provide a modest offset via a potentially value-enhancing clinical expansion and cost controls, but valuation signals are limited due to negative earnings and no dividend.

To see Spark’s full report on ACXP stock, click here.

More about Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat Gram-positive bacterial infections. Its pipeline centers on GPSS-spectrum candidates targeting DNA polymerase IIIC, led by ibezapolstat for Clostridioides difficile infection and additional programs for MRSA, VRE, drug-resistant Streptococcus pneumoniae and anthrax.

Ibezapolstat is Phase 3 ready for international trials in C. difficile infection, and Acurx has launched an open-label pilot trial in multiply-recurrent CDI to inform a subsequent active-controlled Phase 3 registration study. The company also has a preclinical oral candidate for acute bacterial skin and skin structure infections, alongside a planned parallel program for inhaled anthrax treatment.

Average Trading Volume: 3,100,486

Technical Sentiment Signal: Sell

Current Market Cap: $8.85M

See more insights into ACXP stock on TipRanks’ Stock Analysis page.